CONTEXT: The risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (DM) associated with obesity appears to be influenced by the coexistence of other metabolic abnormalities. OBJECTIVE: We examined the risk of developing CVD and DM in metabolically healthy obese (MHO) and metabolically unhealthy normal weight (MUH-NW) individuals. DESIGN AND SETTING: We analyzed prospective data of the San Antonio Heart Study, a population-based study among Mexican Americans and non-Hispanic whites (median follow-up, 7.4 y). PARTICIPANTS: Incident DM and CVD were assessed in 2814 and 3700 participants aged 25 to 64 years, respectively. MAIN MEASURES: MHO was defined as obesity (body mass index ≥ 30 kg/m(2)) with no more than one metabolic abnormality, and MUH-NW was defined as body mass index <25 kg/m(2) with two or more abnormalities. RESULTS: In logistic regression models, BMI was associated with incident DM after controlling for demographics, family history of DM, and fasting glucose (odds ratio × 1 SD, 1.7 [95% CI, 1.5-2.0]). Both MUH-NW and MHO individuals had an increased DM risk (2.5 [1.1-5.6] and 3.9 [2.0-7.4], respectively). Similarly, BMI was related to incident CVD after adjusting for demographics and Framingham risk score (1.3 [1.1-1.6]). Incident CVD was also increased in MUH-NW and MHO individuals (2.9 [1.3-6.4] and 3.9 [1.9-7.8], respectively). Results were consistent across gender and ethnic categories. CONCLUSION: The risk of developing DM and CVD is increased in MUH-NW and MHO individuals. Screening for obesity and other metabolic abnormalities should be routinely performed in clinical practice to institute appropriate preventive measures.
CONTEXT: The risk of cardiovascular disease (CVD) and type 2 diabetes mellitus (DM) associated with obesity appears to be influenced by the coexistence of other metabolic abnormalities. OBJECTIVE: We examined the risk of developing CVD and DM in metabolically healthy obese (MHO) and metabolically unhealthy normal weight (MUH-NW) individuals. DESIGN AND SETTING: We analyzed prospective data of the San Antonio Heart Study, a population-based study among Mexican Americans and non-Hispanic whites (median follow-up, 7.4 y). PARTICIPANTS: Incident DM and CVD were assessed in 2814 and 3700 participants aged 25 to 64 years, respectively. MAIN MEASURES: MHO was defined as obesity (body mass index ≥ 30 kg/m(2)) with no more than one metabolic abnormality, and MUH-NW was defined as body mass index <25 kg/m(2) with two or more abnormalities. RESULTS: In logistic regression models, BMI was associated with incident DM after controlling for demographics, family history of DM, and fasting glucose (odds ratio × 1 SD, 1.7 [95% CI, 1.5-2.0]). Both MUH-NW and MHO individuals had an increased DM risk (2.5 [1.1-5.6] and 3.9 [2.0-7.4], respectively). Similarly, BMI was related to incident CVD after adjusting for demographics and Framingham risk score (1.3 [1.1-1.6]). Incident CVD was also increased in MUH-NW and MHO individuals (2.9 [1.3-6.4] and 3.9 [1.9-7.8], respectively). Results were consistent across gender and ethnic categories. CONCLUSION: The risk of developing DM and CVD is increased in MUH-NW and MHO individuals. Screening for obesity and other metabolic abnormalities should be routinely performed in clinical practice to institute appropriate preventive measures.
Authors: Lars Sjöström; Markku Peltonen; Peter Jacobson; C David Sjöström; Kristjan Karason; Hans Wedel; Sofie Ahlin; Åsa Anveden; Calle Bengtsson; Gerd Bergmark; Claude Bouchard; Björn Carlsson; Sven Dahlgren; Jan Karlsson; Anna-Karin Lindroos; Hans Lönroth; Kristina Narbro; Ingmar Näslund; Torsten Olbers; Per-Arne Svensson; Lena M S Carlsson Journal: JAMA Date: 2012-01-04 Impact factor: 56.272
Authors: Nora Klöting; Mathias Fasshauer; Arne Dietrich; Peter Kovacs; Michael R Schön; Matthias Kern; Michael Stumvoll; Matthias Blüher Journal: Am J Physiol Endocrinol Metab Date: 2010-06-22 Impact factor: 4.310
Authors: Alexandra D Ogorodnikova; Mimi Kim; Aileen P McGinn; Paul Muntner; Unab Khan; Rachel P Wildman Journal: Obesity (Silver Spring) Date: 2011-07-28 Impact factor: 5.002
Authors: J Gómez-Ambrosi; C Silva; J C Galofré; J Escalada; S Santos; D Millán; N Vila; P Ibañez; M J Gil; V Valentí; F Rotellar; B Ramírez; J Salvador; G Frühbeck Journal: Int J Obes (Lond) Date: 2011-05-17 Impact factor: 5.095
Authors: X Julia Xu; Marie-Soleil Gauthier; Donald T Hess; Caroline M Apovian; Jose M Cacicedo; Noyan Gokce; Melissa Farb; Rudy J Valentine; Neil B Ruderman Journal: J Lipid Res Date: 2012-02-08 Impact factor: 5.922
Authors: Francisco B Ortega; Duck-Chul Lee; Peter T Katzmarzyk; Jonatan R Ruiz; Xuemei Sui; Timothy S Church; Steven N Blair Journal: Eur Heart J Date: 2012-09-04 Impact factor: 29.983
Authors: Liming Weng; Eoin Quinlivan; Yan Gong; Amber L Beitelshees; Mohamed H Shahin; Stephen T Turner; Arlene B Chapman; John G Gums; Julie A Johnson; Reginald F Frye; Timothy J Garrett; Rhonda M Cooper-DeHoff Journal: Metab Syndr Relat Disord Date: 2015-02-09 Impact factor: 1.894
Authors: Morgana Mongraw-Chaffin; Meredith C Foster; Rita R Kalyani; Dhananjay Vaidya; Gregory L Burke; Mark Woodward; Cheryl A M Anderson Journal: J Clin Endocrinol Metab Date: 2016-08-23 Impact factor: 5.958